Tirzepatide is usually undetectable in breastmilk with subcutaneous doses of up to 5 mg. Furthermore, absorption by the infant is unlikely because it is probably partially destroyed in the infant's gastrointestinal tract and poorly absorbed orally. If a mother requires tirzepatide, it is not a reason to discontinue breastfeeding. Until more data become available, tirzepatide should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant.
初步证据表明，在剂量高达5毫克的情况下，替尔泊肽在母乳中几乎检测不到。此外，婴儿不太可能吸收，因为它可能在婴儿胃肠道中被部分破坏。如果母亲需要使用替尔泊肽，这不是停止母乳喂养的理由。在获得更多数据之前，哺乳期使用替尔泊肽时应谨慎，尤其是在喂养新生儿或早产儿期间。
